← back to search

Anna Goldenberg

Allen Institute for Artificial Intelligence · CA
Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cancer-related Molecular Pathways, Cancer Genomics and Diagnostics, Bioinformatics and Genomic Networks, and Computational Drug Discovery Methods.
h-index
48
citations
17,171
works
433
NIH funding
primary concept
Medicine
email

Recent publications

Benefit of the N-of-1 Approach Versus Aggregate Analysis in Tracking Individual Trajectories During Pregnancy: Comparison of Longitudinal Wearable Observational Studies.
2026cited by 0position: contributordoi
Digital Health Tools Embedded in a Cancer Genetics Clinic: Observational Study.
2026cited by 0position: contributordoi
Detecting and Remediating Harmful Data Shifts for the Responsible Deployment of Clinical AI Models
JAMA Network Open 2025cited by 32position: middledoi
CANAIRI: the Collaboration for Translational Artificial Intelligence Trials in healthcare
Nature Medicine 2025cited by 20position: middledoi
What makes a ‘good’ decision with artificial intelligence? A grounded theory study in paediatric care
BMJ evidence-based medicine 2025cited by 7position: lastdoi
Maternal health Aggregated Trends can be Misleading: The power of N-of-1 Level Wearable Data Analysis for Personalized Pregnancy Monitoring
2025cited by 0position: contributordoi
Maternal health Aggregated Trends can be Misleading: The power of N-of-1 Level Wearable Data Analysis for Personalized Pregnancy Monitoring (Preprint)
2025cited by 0position: contributordoi
Digital Health Tools Embedded in a Cancer Genetics Clinic: Observational Study (Preprint)
2025cited by 0position: contributordoi
Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA.
2024cited by 32position: contributordoi
Table S1 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 1position: contributordoi
Figure S6 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Figure S1 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Figure S5 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Figure S6 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Table S2 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Figure S2 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Table S2 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Figure S5 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Data from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Figure S2 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Table S6 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Data from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Figure S9 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Figure S7 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Figure S11 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Table S9 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Figure S12 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Table S8 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Figure S12 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi
Table S6 from Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA
2024cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 21 papers (2019–2026)Marzyeh Ghassemi · Institute for Clinical Evaluative Sciences10 papers (2019–2023)Stephen H Friend · American Type Culture Collection9 papers (2021–2026)Sarah M Goodday · University of Oxford9 papers (2021–2026)Adrien Boch · Fitbit (United States)7 papers (2021–2026)Benjamin Haibe‐Kains · Structural Genomics Consortium7 papers (2014–2021)Emma Karlin · 6 papers (2021–2026)Sujay Nagaraj · University of Toronto6 papers (2021–2026) · 5 papers (2021–2022)Zhaleh Safikhani · Roswell Park Comprehensive Cancer Center4 papers (2015–2017)Nehmé El-Hachem · McGill University Health Centre4 papers (2015–2017)Daniel R Karlin · World Trade Organization4 papers (2021–2022)Nancy F Woods · Seattle University4 papers (2021–2022)Luca Foschini · University of Bologna4 papers (2021–2022)Michael D Wilson · Hospital for Sick Children4 papers (2020–2023)Dustin J Sokolowski · SickKids Foundation4 papers (2020–2023)Francesca K Cormack · Newcastle University4 papers (2021–2022)Carol Chapman · University of Toronto4 papers (2021–2022)Abhishek Pratap · American Psychological Association4 papers (2021–2022)Hoora Emami · University of Toronto4 papers (2021–2022)